Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iloprost + eptifibatide
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules, Peptides
- Administration
- Inhalation, Intravenous
01
Overview
Iloprost + eptifibatide is an experimental combination therapy consisting of two agents with complementary mechanisms. Iloprost is a synthetic prostacyclin analog that acts as a potent vasodilator and inhibitor of platelet aggregation, primarily used in pulmonary arterial hypertension and frostbite. Eptifibatide is a cyclic heptapeptide derived from snake venom that functions as a selective, reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation and used mainly in acute coronary syndromes and percutaneous coronary intervention. The combination has been studied experimentally for its potential to reduce endothelial injury, modulate inflammation, decrease platelet consumption, and improve outcomes in septic shock by targeting both endothelial activation (via iloprost) and platelet function (via eptifibatide)[1][4]. This dual approach aims to interrupt the cycle of microvascular injury characteristic of severe sepsis.
- Brand names
- Ventavis (iloprost)Aurlumyn (iloprost)Integrilin (eptifibatide)
- Other names
- Iloprost and Eptifibatide co-administration
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on iloprost + eptifibatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iloprost + eptifibatide.